Pharmacovigilance Risk Assessment Committee.
- Published in:
- 2012
- Publication type:
- Journal Article
Works matching IS 10109609 AND DT 2012 AND VI 26 AND IP 3
Results: 41
1
2
Pyrantel oral suspension.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 297
- Publication type:
- Article
3
Abacavir oral solution Abacaviri solutionum peroralum.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 293
- Publication type:
- Article
4
Revision of monograph on capsules.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 289
- Publication type:
- Article
5
The International Pharmacopoeia.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 284
- Publication type:
- Article
6
Assessing risk of resistance in antimalarial compounds.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 283
- Publication type:
- Article
7
Procurement of reproductive health supplies.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 283
- Publication type:
- Article
8
HIV treatment in twenty-three countries.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 282
- Publication type:
- Article
9
Patent searches on essential medicines.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 282
- Publication type:
- Article
10
Pharmacovigilance: towards a safer use of medicines.
- Published in:
- 2012
- Publication type:
- Book Review
11
Paediatric morphine dosage.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 278
- Publication type:
- Article
12
Lenalidomide: withdrawal of marketing authorization application.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 277
- Publication type:
- Article
13
Tesamorelin: withdrawal of marketing authorization application.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 276
- Publication type:
- Article
14
Semuloparin sodium: withdrawal of marketing authorization application.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 276
- Publication type:
- Article
15
Trimetazidine-containing medicines: restricted use.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 276
- Publication type:
- Article
16
Tolperisone: restricted use.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 275
- Publication type:
- Article
17
Teduglutide approved for short bowel syndrome.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 275
- Publication type:
- Article
18
Alipogene tiparvovec approved for lipoprotein lipase deficiency.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 275
- Publication type:
- Article
19
Lorcaserin approved for overweight or obese adults.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 274
- Publication type:
- Article
20
Mirabegron approved for overactive bladder.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 274
- Publication type:
- Article
21
Emtricitabine/tenofovir disoproxil fumarate approved for HIV.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 273
- Publication type:
- Article
22
Online publication of suspected side-effect reports.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 273
- Publication type:
- Article
23
Dabigatran: positive benefit-risk balance.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 272
- Publication type:
- Article
24
Doripenem: dosing review for nosocomial pneumonia.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 272
- Publication type:
- Article
25
Calcitonin medicines: limit long-term use.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 271
- Publication type:
- Article
26
Denosumab: severe hypocalcaemia.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 271
- Publication type:
- Article
27
Human immune globulin: haemolytic reactions.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 270
- Publication type:
- Article
28
Hepatitis B immune globulin: thrombotic events.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 270
- Publication type:
- Article
29
Ambrisentan: idiopathic pulmonary fibrosis.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 270
- Publication type:
- Article
30
Serotonergic medicines: cerebral vasoconstriction syndrome.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 269
- Publication type:
- Article
31
Somatropin: Increased risk of mortality?
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 268
- Publication type:
- Article
32
Statins and ciclosporin: risk of myopathy.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 267
- Publication type:
- Article
33
Boceprevir: drug interaction.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 267
- Publication type:
- Article
34
Aprotinin: restricted access programme.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 267
- Publication type:
- Article
35
Strontium ranelate: serious skin reactions.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 266
- Publication type:
- Article
36
Vessel sealing system: torn vessels.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 266
- Publication type:
- Article
37
Cefepime: risk of seizure.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 265
- Publication type:
- Article
38
Extended-release and long-acting opioid medications.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 265
- Publication type:
- Article
39
Ondansetron: QT prolongation.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 265
- Publication type:
- Article
40
WHO Prequalification of Medicines Programme.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 248
- By:
- Publication type:
- Article
41
Regulator prequalification of medicines: a future concept for networking.
- Published in:
- WHO Drug Information, 2012, v. 26, n. 3, p. 239
- Publication type:
- Article